ELF Patient Organisation network

Covers:

• Acute lower respiratory infections
• Acute respiratory distress syndrome
• Acute respiratory failure
• Adult asthma
• Allergies
• Allergy
• Alpha-1 antitrypsin deficiency
• Aspergillosis
• Asthma
• Bronchiectasis
• Bronchiolitis
• Bronchopulmonary dysplasia
• Childhood asthma
• COPD
• Cough
• COVID-19
• Croup
• Cystic fibrosis
• Histiocytosis
• Idiopathic interstitial pneumonia
• Idiopathic pulmonary fibrosis
• Interstitial lung disease
• IPF
• LAM
• Laryngotracheobronchitis
• Lung cancer
• Lung disease in children
• Lung metastases
• Lung surgery
• Lung transplantation
• Mediastinal tumors
• Mesothelioma
• Non-tuberculosis mycobacteria
• Occupational lung disease
• Other lung diseases
• Pneumonia
• Pneumothorax
• Primary Ciliary Dyskinesia (PCD)
• Pulmonary arterial hypertension
• Pulmonary embolism
• Pulmonary Fibrosis
• Pulmonary Hypertension
• Pulmonary vascular disease
• Rare and orphan lung disease
• Rare ILD/DPLD
• Sarcoidosis
• Sleep apnoea
• Sleep breathing disorders
• Sleep disordered breathing
• Smoking cessation
• Tuberculosis
• Upper airways diseases

A tot pulmó is a non-profit association of patients, caregivers and professionals interested in respiratory diseases in Spain. Our goal is to support, assist and help those affected by these problems, improving their knowledge about the disease and its treatments.

Covers:

• Pulmonary Fibrosis

Action for Pulmonary Fibrosis (APF) is a growing community of patients, families, researchers and healthcare professionals striving to find a cure for pulmonary fibrosis so that everyone affected by the disease has a better future. We provide personalised support to patients and families – and raise awareness of pulmonary fibrosis through campaigning, fundraising and education. We are also committed to funding research to improve quality of life for people living with pulmonary fibrosis today and tomorrow.

Covers:

• Allergy
• Asthma

aha! Swiss Allergy Centre

aha! Swiss Allergy Centre, a centre of excellence in the areas of allergy, skin, asthma and intolerance, offers information, advice and training courses to sufferers, but also to businesses, training centres, authorities, associations and other groups and it runs prevention and information campaigns.

Covers:

• Rare and orphan lung disease

National Alliance for Rare Diseases Romania (ANBRaRo)

The National Alliance for Rare Diseases in Romania was established at the initiative of the Prader Willi Association in Romania in August 2007, through a project funded by CEE Trust. To found the Alliance, 32 founding members have joined forces: rare disease organisations and patient groups for whom the disease is so rare that there is no association.

ANBRaRo's mission is to develop and carry out lobbying and advocacy activities to improve the quality of life of patients with rare diseases in Romania.

Purpose: To increase the responsibility of the community towards patients affected by rare diseases by involving social actors in this field: patients, families, specialists and authorities.

General objective: improving the quality of life of people with rare diseases in Romania.

Covers:

• Allergies
• Allergy
• Asthma

Allergy & Asthma Organization of Kenya is a registered not-for-profit patient driven organisation in Kenya. It endeavours to create public awareness creation, education, advocacy, testing and research on allergy, asthma, COPD and respiratory conditions.

Covers:

• Alpha-1 antitrypsin deficiency

Raising awareness and supporting sufferers of, and research into, Alpha-1 Antitrypsin Deficiency - a genetic condition that causes lung and liver problems.

Covers:

• Alpha-1 antitrypsin deficiency

Alpha-1 Foundation Ireland was founded in 2001 and is based in the RCSI Education and Research Centre at Beaumont Hospital. We are dedicated to raising awareness, increasing diagnosis, promoting research, and improving the treatment of Alpha-1. Our vision is that every person with Alpha-1 in Ireland is diagnosed and receives specialist care and treatment in a timely fashion.

Covers:

• Alpha-1 antitrypsin deficiency

Our mission is to develop a collaborative global network of Alpha-1 patient leaders, physicians, and researchers, to increase awareness, detection, and access to care for Alphas around the world.

Covers:

• Alpha-1 antitrypsin deficiency

Alpha-1 Plus asbl is a patient driven association for advocacy in Alpha-1 antitrypsin deficiency.

Covers:

• Alpha-1 antitrypsin deficiency

We are the UK's premier charity for patients and families affected by alpha-1 antitrypsin deficiency. We have a 21-year history of providing information, advice and practical and financial support to alpha-1 patients. The Alpha-1 UK Support Group is campaigning to heighten the awareness of alpha-1 and the burden of living with this disease. We work collaboratively with expert clinicians and politicians to effectively communicate the unmet needs of the patient community to policy makers. We design and drive initiatives to improve access to adequate healthcare services and effective treatments for Alpha-1 patients across the UK.

Covers:

• Alpha-1 antitrypsin deficiency

Alpha1 Germany

Alpha1 Deutschland e. V. was established in 2001 and is one of the largest alpha-1 patient organisations in Europe. We aim to make the everyday lives of affected patients and their relatives easier, provide information about the disease and take away fears. We promote and train regional support groups. Another important goal is to raise awareness of the disease among doctors and researchers as well as the public. For this reason, we organise regular information events for adults and children, to which we invite speakers who have been involved with AAT deficiency for many years.

Covers:

• Sarcoidosis

Friends Against Sarcoidosis Italy (ACSI)

ACSI is the only national Association in Italy dealing with Sarcoidosis, supporting patients, in terms of information and assistance. It supports physicians and researchers in their medical and science activities, by improving knowledge and awareness and supporting research economically.

Covers:

• Sleep apnoea

Apnoea Association Belgium Flanders (APNEUVL)

Covers:

• Alpha-1 antitrypsin deficiency

Spanish Alpha-1 Patients’ Association (Alfa-1 España)

Covers:

• Pneumonia

Association for the Support of Patients with Pneumonia and their Families (NEUMOAI), Spain

NEUMOAI is a non-profit organisation in Spain that aims give visibility and raise awareness about pneumonia.

Covers:

• Allergies
• Allergy
• Asthma

Association of Asthma and Allergy Patients "Aire Libre" of Granada, Spain

Aire Libre is a not-for-profit organisation of mutual support, with the primary purpose to promote all kinds of actions and care, health and scientific activities dedicated to improving the quality of life of all people affected by respiratory problems.

Covers:

• Idiopathic pulmonary fibrosis

Association of Relatives and Patients with IPF (AFEFPI)

AFEFPI is a national association made up of relatives and patients with idiopathic pulmonary fibrosis (IPF) and Familial Pulmonary Fibrosis (FPF) (cases of IPF that are grouped in families, that is to say, two or more cases in the same family).

The association was created in 2008 in order to join the efforts of all those who in one way or another are interested in the disease (doctors, patients, relatives) who want to collaborate and support those affected by this disease.

Covers:

• COPD

Spanish patient organisation of COPD (APEPOC)

APEPOC is a non-profit organisation that is included in those regulated by articles 16 and 2 of Law 49/2002, of December 23, 2002, on the tax regime of non-profit organisations and tax incentives for patronage, with its own legal personality, which pursues general interest purposes, and whose objectives, among others, the defense of the rights of COPD patients. All the actions carried out by this association will ultimately aim to improve the quality of life of COPD patients. In order to achieve this objective, it mainly uses two ways: the assistance services to its associates, and the dissemination of the disease as a means to pressure the administrations to invest in quality of life for COPD patients.